This award recognizes researchers whose work demonstrates exceptional originality, independence of thought, and significant impact in the field of diabetes research. Timo Müller’s pioneering discoveries have reshaped the scientific understanding of obesity and diabetes, providing foundational insights into central nervous system GIP receptor biology and paving the way for the development of next-generation incretin-based polyagonists. His work has substantially advanced therapeutic strategies and opened new avenues for the treatment of metabolic diseases.
With more than 200 publications in leading scientific journals, Müller is widely recognized as a global leader in metabolic research, driving transformative advances in diabetes science and metabolic medicine.
“The ADA is pleased to recognize these individuals and the vital role they play in advancing our mission to prevent and cure diabetes and improve the lives of all people affected by diabetes. Their incredible contributions are moving us closer to a world free of diabetes and all its burdens,” said Charles “Chuck” Henderson, Chief Executive Officer of the ADA.
The award recipients will be honored during an awards ceremony at the ADA’s 2026 Scientific Sessions, taking place in June. The Scientific Sessions represent the world’s largest scientific meeting dedicated to diabetes research, prevention, and care.
About the American Diabetes Association
The American Diabetes Association (ADA) is a leading nonprofit health organization in the United States, focused on the prevention and treatment of diabetes as well as supporting people living with the condition.
Contact:
Prof. Dr. Timo Müller
Head of the Institute for Diabetes and Obesity and of its Research Unit Molecular Pharmacology
+49 89 3187 2106
timo.mueller@helmholtz-munich.de
Helmholtz Munich is a top biomedical research center. Its mission is to develop pioneering solutions for a healthier society in a rapidly changing world. Interdisciplinary research teams focus on environmental diseases, in particular the treatment and prevention of diabetes, obesity, allergies and chronic lung diseases. www.helmholtz-munich.de/en
The German Center for Diabetes Research (DZD) is a national association that brings together experts in the field of diabetes research and combines basic research, translational research, epidemiology and clinical applications. The aim is to develop novel strategies for personalized prevention and treatment of diabetes. Members are Helmholtz Munich – German Research Center for Environmental Health, the German Diabetes Center in Düsseldorf, the German Institute of Human Nutrition in Potsdam-Rehbrücke, the Paul Langerhans Institute Dresden of Helmholtz Munich at the University Medical Center Carl Gustav Carus of the TU Dresden and the Institute for Diabetes Research and Metabolic Diseases of Helmholtz Munich at the Eberhard-Karls-University of Tuebingen together with associated partners at the Universities in Heidelberg, Cologne, Leipzig, Lübeck and Munich. www.dzd-ev.de/en
